Differential expression of matrix metalloproteinases and proteoglycans in Juvenile Hyaline Fibromatosis

Journal of Dermatological Science

Volumn 61, Issue 2, 2011, Pages 94-100

  Tzellos, Thrasivoulos G ^a   Batzios, Spyros P ^a   Dionyssopoulos, Alexander ^a   Karakiulakis, George ^a   Papakonstantinou, Eleni ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Extracellular matrix; Gelatinases; Juvenile Hyaline Fibromatosis; Matrix metalloproteinases; Proteoglycans; Tissue inhibitors of matrix metalloproteinases

Indexed keywords

AGGRECAN; DECORIN; GELATINASE A; GELATINASE B; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MATRIX METALLOPROTEINASE; PROTEOGLYCAN; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ARTICLE; CASE REPORT; CHILD; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; HUMAN; HUMAN TISSUE; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; SYSTEMIC HYALINOSIS; UPREGULATION; ZYMOGRAPHY;

AGGRECANS; BIGLYCAN; CHILD; DECORIN; DOWN-REGULATION; ENZYME PRECURSORS; EXTRACELLULAR MATRIX; FEMALE; GELATINASES; GENE EXPRESSION; HEPARAN SULFATE PROTEOGLYCANS; HUMANS; HYALINOSIS, SYSTEMIC; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; SKIN; STATISTICS, NONPARAMETRIC; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; UP-REGULATION;

EID: 78951485845     PISSN: 09231811     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2010.12.002     Document Type: Article

References (43)

1. Dowling O., Difeo A., Ramirez M.C., Tukel T., Narla G., Bonafe L., et al. Mutations in capillary morphogenesis gene-2 result in the allelic disorders juvenile hyaline fibromatosis and infantile systemic hyalinosis. Am J Hum Genet 2003, 73:957-966.
2. Tanaka K., Ebihara T., Kusubata M., Adachi E., Arai M., Kawaguchi N., et al. Abnormal collagen deposition in fibromas from patient with juvenile hyaline fibromatosis. J Dermatol Sci 2009, 55:197-200.
3. Haleem A., Al-Hindi H.N., Juboury M.A., Husseini H.A., Ajlan A.A. Juvenile hyaline fibromatosis. Morphologic, immunohistochemical and ultrastructural study of three siblings. Am J Dermatopathol 2002, 24:218-224.
4. Iwata S., Horiuchi R., Maeda H., Ishikawa H. Systemic hyalinosis or juvenile hyaline fibromatosis. Ultrastructural and biochemical study of cultured skin fibroblasts. Arch Dermatol Res 1980, 267:115-121.
5. Mayer-da-Silva A., Poiares-Baptista A., Guerra Rodrigo F., Teresa-Lopes M. Juvenile hyaline fibromatosis. A histologic and histochemical study. Arch Pathol Lab Med 1988, 12. 928-311.
6. Winik B.C., Boente M.C., Asial R. Juvenile hyaline fibromatosis: ultrastructural study. Am J Dermatopathol 1998, 20:373-378.
7. Hanks S., Adams S., Douglas J., Arbour L., Atherton D.J., Balci S., et al. Mutations in the gene encoding capillary morphogenesis protein 2 cause juvenile hyaline fibromatosis and infantile systemic hyalinosis. Am J Hum Genet 2003, 73:791-800.
8. Shieh J.T., Swidler P., Martignetti J.A., Ramirez M.C., Balboni I., Kaplan J., et al. Systemic hyalinosis: a distinctive early childhood-onset disorder characterized by mutations in the anthrax toxin receptor 2 gene (ANTRX2). Pediatrics 2006, 118:1485-1492.
9. DeRosa G., Tornillo L., Orabona P., D'Antonio A., Staibano S., Boscaino A. Juvenile hyaline fibromatosis: a case report of a localized form?. Am J Dermatopathol 1994, 16:624-627.
10. Remberger K., Krieg T., Kunze D., Weinmann H.M., Hubner G. Fibromatosis hyalinica multiplex (juvenile hyaline fibromatosis). Light microscopic, electron microscopic, immunohistochemical and biochemical findings. Cancer 1985, 56:614-624.
11. Katagiri K., Takasaki S., Fujiwara S., Kayashima K., Ono T., Shinkai H. Purification and structural analysis of extracellular matrix of a skin tumor from a patient with juvenile hyaline fibromatosis. J Dermatol Sci 1996, 13:37-48.
12. Larralde M., Santos-Munoz A., Calb I., Magarinos C. Juvenile hyaline fibromatosis. Pediatr Dermatol 2001, 18:400-402.
13. Lubec B., Steinert I., Breier F., Jurecka W., Pillwein K., Fang-Kircher S. Skin collagen defects in a patient with juvenile hyaline fibromatosis. Arch Dis Child 1995, 73:246-248.
14. Breier F., Fang-Kircher S., Wolff K., Jurecka W. Juvenile hyaline fibromatosis: impaired collagen metabolism in culture skin fibroblasts. Arch Dis Child 1997, 77:436-440.
15. Nagase H., Woessner J.F. Matrix metalloproteinases. J Biol Chem 1999, 274:21491-21494.
16. Woessner J.F. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 1991, 5:2145-21454.
17. Ohnishi Y., Ito Y., Tajima S., Ishibashi A., Arai K. Immunohistochemical study of membrane type-matrix metalloproteinases (MT-MMPs) and matrix metalloproteinase-2 (MMP-2) in dermatofibroma and malignant fibrous histiocytoma. J Dermatol Sci 2002, 28:119-125.
18. Rydlova M., Holubec L., Ludvikova M., Kalfert D., Franekova J., Povysil C, et al. Biological activity and clinical implications of the matrix metalloproteinases. Anticancer Res 2008, 28:1389-1397.
19. Brew K., Dinakarpandian D., Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 2000, 1477:267-283.
20. Clark I.M., Swingler T.E., Sampieri C.L., Edwards D.R. The regulation of matrix metalloproteinases and their inhibitors. Int J Biochem Cell Biol 2008, 40:1362-1378.
21. Iozzo R.V. Matrix proteoglycans from molecular design to cellular function. Ann Rev Biochem 1998, 67:609-652.
22. Hardingham T.E., Fosang A.J. Proteoglycans: many forms and many functions. FASEB J 1992, 6:861-870.
23. Papakonstantinou E., Aletras A.J., Glass E., Tsogas P., Dionyssopoulos A., Adjaye J., et al. Matrix metalloproteinases of epithelial origin in facial sebum of patients with acne and their regulation by isotretinoin. J Invest Dermatol 2005, 125:673-684.
24. Papakonstantinou E., Dionyssopoulos A., Aletras A.J., Pesintzaki C., Minas A., Karakiulakis G. Expression of matrix metalloproteinases and their endogenous tissue inhibitors in skin lesions from patients with tuberous sclerosis. J Am Acad Dermatol 2004, 51:526-533.
25. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254.
26. Barber R.D., Harmer D.W., Coleman R.A., Clark B.J. GAPDH as a housekeeping gene: analysis of GAPDH mRNA expression in a panel of 72 human tissues. Physiol Genomics 2005, 21:389-395.
27. Tzellos T.G., Dionyssopoulos A., Klagas I., Karakiulakis G., Lazaridis L., Papakonstantinou E. Differential glycosaminoglycan expression and hyaluronan homeostasis in juvenile hyaline fibromatosis. J Am Acad Dermatol 2009, 61:629-638.
28. Maioli E., Fortino V., Torricelli C., Arezzini B., Gardi C. Effect of parathyroid hormone-related protein on fibroblast proliferation and collagen metabolism in human skin. Exp Dermatol 2002, 11:302-310.
29. Kerkela E., Saarialho-Kere U. Matrix metalloproteinases in tumor progression: focus on basal and squamous cell skin cancer. Exp Dermatol 2003, 12:109-125.
30. Hayakawa T., Yamashita K., Shinagawa A. Cell growth promoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2). J Cell Sci 1994, 107:2372-2379.
31. Zyada M.M. Expression of matrix metalloproteinase-9 and significance of a macrophage assay in eosinophilic granuloma. Ann Diagn Pathol 2009, 13:367-372.
32. O'Grady A., Dunne C., O'Kelly P., Murphy G.M., Leader M., Kay E. Differential expression of matrix metalloproteinase (MMP)-2. MMP-9 and tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2 in non-melanoma skin cancer: implications for tumour progression. Histopathology 2007, 51:793-804.
33. Imaizumi R., Akasaka Y., Inomata N., Okada E., Ito K., Ishikawa Y., et al. Promoted activation of matrix metalloproteinase (MMP)-2 in keloid fibroblasts and increased expression of MMP-2 in collagen bundle regions: implications for mechanisms of keloid progression. Histopathology 2009, 54:722-730.
34. Bran G.M., Goessler U.R., Baftiri A., Hormann K., Riedel F., Sadick H. Effect of transforming growth factor-beta1 antisense oligonucleotides on matrix metalloproteinases and their inhibitors in keloid fibroblasts. Otolaryngol Head Neck Surg 2010, 143:66-71.
35. Senzaki H., Kiyozuka Y., Uemura Y., Shikata N., Ueda S., Tsubura A. Juvenile hyaline fibromatosis: a report of two unrelated adult sibling cases and a literature review. Pathol Int 1998, 48:230-236.
36. Hakki S.S., Balci B., Hakki E.E., Yilmaz E., Nohutcu R.M. Identification of the difference in ECM and adhesion molecules of cultured human gingival fibroblasts versus juvenile hyaline fibromatosis gingival fibroblasts using cDNA microarray analysis. J Periodontol 2005, 76:2244-2253.
37. Rinn J.L., Wang J.K., Liu H., Montgomery K., van de Rijn M., Chang H.Y. A systems biology approach to anatomic diversity of skin. J Invest Dermatol 2008, 128:776-782.
38. Chang H.Y., Chi J.T., Dudoit S., Bondre C., van de Rijn M., Botstein D., et al. Diversity, topographic differentiation, and positional memory in human fibroblasts. Proc Natl Acad Sci USA 2002, 99:12877-12882.
39. Kuwaba K., Kobayashi M., Nomura Y., Irie S., Koyama Y. Size control of decorin dermatan sulfate during remodeling of collagen fibrils in healing skin. J Dermatol Sci 2002, 29:185-194.
40. Sher I., Zisman-Rozen S., Eliahu L., Whitelock J.M., Maas-Szabowski N., Yamada Y., et al. Targeting perlecan in human keratinocytes reveals novel roles for perlecan in epidermal formation. J Biol Chem 2006, 281:5178-5187.
41. Lemire J.M., Patis C., Gordon L.B., Sandy J.D., Toole B.P., Weiss A.S. Aggrecan expression is substantially and abnormally upregulated in Hutchinson-Gilford Progeria Syndrome dermal fibroblasts. Mech Ageing Dev 2006, 127:660-669.
42. El Bradey M., Cheng L., Bartsch D.U., Appelt K., Rodanant N., Bergeron-Lynn G., et al. Preventive versus treatment effect of AG3340, a potent matrix metalloproteinase inhibitor in a rat model of choroidal neovascularization. J Ocul Pharmacol Ther 2004, 20:217-236.
43. Skiles J.W., Gonella N.C., Jeng A.Y. The design, structure and therapeutic application of matrix metalloproteinase inhibitors. Curr Med Chem 2001, 8:425-474.